Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapyDemonstrates potential of stem cell memory T cells (TSCM), a key differentiator for Poseida's CAR-T programs SAN DIEGO, Sept. 4, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, highlighted new data from ...

Core Viewpoint - Anixa Biosciences is advancing its ovarian cancer CAR-T technology, specifically the chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) and is currently in a Phase 1 clinical trial [2][3][4]. Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4]. - The company also has a vaccine portfolio aimed at preventing triple negative breast cancer (TNBC) and ovarian cancer, along with other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4]. Technology Details - The CAR-T technology being developed by Anixa is an autologous cell therapy that utilizes engineered T cells to specifically target FSHR, which is present on granulosa cells of the ovaries [2]. - This innovative approach is referred to as CER-T therapy, distinguishing it from traditional CAR-T therapies due to its targeting of a hormone receptor [2]. Clinical Development - Dr. Jose R. Conejo-Garcia will present the ongoing Phase 1 clinical trial results at the upcoming Ovarian Cancer Research Symposium, highlighting the safety and tolerability of the treatment, with some patients showing signs of tumor necrosis [3].

Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company’s next-genera ...

Rost-9D/iStock via Getty ImagesAllogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotech company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. ALLO uses advanced gene-editing platforms like TALEN and CRISPR/Cas9 to engineer donor-derived T cells. These off-the-shelf treatments overcome the limitations of autologous therapies by targeting and killing malignant cells. The company’s robust pipeline covers hematologic malignancie ...

Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). GLPG5101 is an autologous CD19 CAR-T cell therapy product candidate produc ...

georgeclerk Summary We maintain our Hold rating on Canadian Apartment Properties Real Estate Investment Trust (TSX:CAR.UN:CA / OTC:CDPYF). While operational performance has remained solid, we believe there are far more attractive risk/return profiles within Canadian residential REITs, such as Northview Residential REIT. The current price's proximity to our NAV estimate leads us to believe that unit performance over the short term should follow NOI and FFO growth (i.e., sector performance). We need to se ...

HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has been awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the clinical investigation of MT-601 in patients with non-Hodgkin’ ...

Avis Budget Group, Inc. (CAR) reported lower-than-expected second-quarter 2024 results.The stock has increased 6.3% since its earnings release on Aug 5 despite the earnings and revenue miss.CAR’s earnings of 41 cents per share missed the Zacks Consensus Estimate by 84.2% and decreased 96.3% from the year-ago quarter’s actual. Total revenues of $3 billion missed the consensus estimate by 4% and decreased 2.4% on a year-over-year basis.Avis Budget’s shares have declined 47% in the past six months compared wit ...

Financial Data and Key Metrics Changes - The company reported quarterly revenue exceeding $3 billion and adjusted EBITDA of $214 million for Q2 2024 [7][23][24] - Adjusted EBITDA was impacted by non-recurring fleet gains and increased vehicle interest, with a year-over-year variance of $245 million attributed to vehicle dispositions [24][25] - Straight-line depreciation increased from approximately $280 per unit per month to nearly $330, with expectations of $350 for the remainder of the year [25][26] Business Line Data and Key Metrics Changes - The Americas segment generated nearly $2.4 billion in revenue with adjusted EBITDA of $186 million, with rental days up 1% year-over-year [10][15] - International revenue was nearly $700 million with adjusted EBITDA of $48 million, down 1% year-over-year, but flat on a constant currency basis [16][17] Market Data and Key Metrics Changes - Pricing in the Americas improved sequentially, with June showing a 2% decrease year-over-year but still significantly higher than 2019 levels [11][12] - International pricing was down 5% year-over-year, but also showed improvement month-over-month throughout the quarter [17][18] Company Strategy and Development Direction - The company aims to prioritize pricing over volume, focusing on maintaining fleet size in line with demand to enhance margin benefits [10][12] - A strong emphasis on technology and analytics is being placed to improve operational efficiencies and customer experience [19][20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the robust demand environment, with record-setting volume in the Americas and positive trends expected to continue into the summer [8][15] - The company anticipates adjusted EBITDA for Q3 2024 to be in the range of $500 million to $600 million, supported by strong summer demand [33][35] Other Important Information - The company has completed approximately 70% of its expected full-year vehicle dispositions, positioning itself for higher utilizations in the upcoming quarters [23][31] - Liquidity as of June 30 was over $800 million, with additional borrowing capacity of approximately $2.9 billion [31][32] Q&A Session Summary Question: Is there a seismic shift in the industry landscape regarding competitor fleet actions? - Management noted that while they prefer pricing over volume, they still achieved record demand in Q2, indicating no significant shifts in competitor actions [36][37] Question: What percentage of model year 2025 purchases has been completed? - Management indicated they are about halfway through their model year 2025 purchases, with significant improvements in holding costs [39][40] Question: Can you elaborate on liquidity and potential cash extraction from fleet securitization? - Management confirmed they have over $1 billion in liquidity cushion and the ability to issue more than $1 billion of debt from financing structures [44][45] Question: Are there plans to refresh the fleet, and what is the ideal utilization level? - Management stated they are continuously monitoring fleet size and demand, aiming for better utilization through data analytics [49][54] Question: How does the company view potential recessionary impacts on used vehicle values? - Management expressed confidence in their ability to manage depreciation and protect against downturns, citing past experiences and current strategies [63][66]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File No. 001-10308 Avis Budget Group, Inc. (Exact name of registrant as specified in its charter) Delaware 06-0918165 (State o ...